Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 has completed the Phase I clinical trial in China and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company's RlPK2 inhibitor AC-101 has completed the Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed the Phase I trial in Australia and China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets including the US, the EU, China, Japan, and Korea.